ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,304.98
1.11%
Dow Jones
39,889.39
0.84%
US Dollar vs MXN
16.69222
-0.92%
Brent Oil
82.70
0.18%
Bitcoin
66,089.51
7.38%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. NeuroSense Therapeutics Ltd (NRSN)

  7. NeuroSense Therapeutics Ltd (NRSN) Noticias

NRSN

NeuroSense Therapeutics (NRSN)

NeuroSense Therapeutics Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:NRSN
FechaHoraFuenteTítuloSímboloCompañía
14/05/202408:05PR Newswire (US)NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningNASDAQ:NRSNNeuroSense Therapeutics Ltd
07/05/202407:45PR Newswire (US)NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsNASDAQ:NRSNNeuroSense Therapeutics Ltd
02/05/202408:19PR Newswire (US)NeuroSense Announces First Quarter 2024 Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
22/04/202407:30PR Newswire (US)NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseNASDAQ:NRSNNeuroSense Therapeutics Ltd
18/04/202407:30PR Newswire (US)NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingNASDAQ:NRSNNeuroSense Therapeutics Ltd
12/04/202407:30PR Newswire (US)NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024NASDAQ:NRSNNeuroSense Therapeutics Ltd
10/04/202418:16PR Newswire (US)NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/04/202407:30PR Newswire (US)NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/04/202408:29PR Newswire (US)NeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
22/02/202407:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
21/02/202407:30PR Newswire (US)NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
13/02/202412:20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRSNNeuroSense Therapeutics Ltd
07/02/202408:27PR Newswire (US)NeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/01/202407:45PR Newswire (US)NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsNASDAQ:NRSNNeuroSense Therapeutics Ltd
27/12/202316:03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
27/12/202316:00PR Newswire (US)NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementNASDAQ:NRSNNeuroSense Therapeutics Ltd
14/12/202308:24PR Newswire (US)NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/12/202307:00PR Newswire (US)NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/12/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/12/202315:01PR Newswire (US)NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023NASDAQ:NRSNNeuroSense Therapeutics Ltd
04/12/202305:17Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NRSNNeuroSense Therapeutics Ltd
28/11/202307:45PR Newswire (US)NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
13/11/202308:20PR Newswire (US)NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial ReadinessNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/11/202308:00PR Newswire (US)NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS ConferencesNASDAQ:NRSNNeuroSense Therapeutics Ltd
06/11/202307:30PR Newswire (US)NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023NASDAQ:NRSNNeuroSense Therapeutics Ltd
01/11/202308:00PR Newswire (US)NeuroSense Therapeutics to Participate in BIO-Europe FallNASDAQ:NRSNNeuroSense Therapeutics Ltd
17/10/202307:30PR Newswire (US)NeuroSense CEO Provides Q3 2023 UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/10/202308:10PR Newswire (US)NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC ModelNASDAQ:NRSNNeuroSense Therapeutics Ltd
20/09/202308:05PR Newswire (US)European Medicines Agency Grants NeuroSense SME StatusNASDAQ:NRSNNeuroSense Therapeutics Ltd
19/09/202308:00PR Newswire (US)NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeCNASDAQ:NRSNNeuroSense Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:NRSN

Su Consulta Reciente

COIN
CNTMBTC
BIT
P166Z1
BNP Paribas Issuance
BIT
P1AJ68
BNP Paribas Issuance
UNSW3
IAGETH
IAGON
USOTC
VIPRF
Silver Viper Minerals (QB)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados